人抗鼠抗体反应（HAMA）非常严重地影响鼠源抗体治疗的安全性和疗效。抗体人源化已经成为将鼠源抗体转化为有效安全的治疗药物的重要方式。苏州智享基于业界领先的抗体工程和重组抗体生产平台，可为客户提供高质量的抗体人源化与亲和力成熟一体化服务。基于CDR移植与回复突变原理，结合生物信息学和结构生物学手段辅助设计与优化，我们的人源化平台可以快速、有效地减弱抗体蛋白的免疫原性，同时保持较高的亲和力、活性、稳定性和产量。
Human anti-mouse antibody response (HAMA) severely affects the safety and efficacy of mouse-derived antibody therapy. Antibody humanization has become an important method to convert murine antibodies into effective and safe therapeutic drugs. With industry-leading antibody engineering and recombinant antibody production platforms, IntellectiveBio can provide our clients with high-quality integrated services of antibody humanization and affinity maturity. Based on the principle of CDR transplantation and recovery mutation, our humanization platform, combined with bioinformatics and structural biology to assist design and optimization, can quickly and effectively weaken the immunogenicity of antibodies while maintaining a high affinity, activity, stability and yield.
- 可变区建模Variable Zone Modeling
- 人源化设计Humanization Design
- 翻译后修饰预测Post-translational Modifications (PTMs) Prediction
- 候选制备Candidate Preparation
- 亲和力检测Affinity Test
